Holen Sie sich die Stockscreener-App
2.67
1.52%
0.04
Vorhandelsmarkt:
2.67
Schlusskurs vom Vortag:
$2.63
Offen:
$2.61
24-Stunden-Volumen:
3.20M
Relative Volume:
1.53
Marktkapitalisierung:
$227.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-1.9209
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+1.91%
1M Leistung:
+44.32%
6M Leistung:
+52.57%
1J Leistung:
+40.90%
1-Tages-Spanne:
$2.55
$2.67
1-Wochen-Bereich:
$2.50
$2.728
52-Wochen-Spanne:
$0.6254
$2.77
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Vergleichen Sie MIST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.67 | 224.00M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
Is Milestone Pharmaceuticals Inc. stock recession proofDip Buying & Long-Term Growth Stock Strategies - Newser
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
EV Market: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Momentum & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Milestone Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Volatility Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Healthy Upside Potential: Milestone Pharmaceuticals Inc (MIST) - Setenews
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Insider Monkey
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Grasim Industries Limited Trading Near Value Zone Recovery AheadRetail Investor Activity & Low Entry Risk Stocks - earlytimes.in
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 17:33:54 - newser.com
Why analysts remain bullish on Milestone Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 13:39:11 - newser.com
It makes sense and dollars to buy Milestone Pharmaceuticals Inc (MIST) stock - Setenews
Published on: 2025-11-19 06:17:41 - newser.com
Using Bollinger Bands to evaluate Milestone Pharmaceuticals Inc.Weekly Volume Report & AI Powered Market Entry Ideas - newser.com
How Milestone Pharmaceuticals Inc. stock reacts to oil pricesTreasury Yields & Daily Market Momentum Tracking - newser.com
How to forecast Milestone Pharmaceuticals Inc. trends using time series2025 Year in Review & Stock Portfolio Risk Control - newser.com
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate - Yahoo Finance
What is HC Wainwright's Estimate for MIST FY2025 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for MIST FY2025 Earnings? - Defense World
Will Milestone Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Volume Leaders & Weekly Momentum Picks - newser.com
Can Milestone Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Expert Approved Trade Ideas - newser.com
Is it too late to sell Milestone Pharmaceuticals Inc.Weekly Stock Report & Safe Swing Trade Setups - newser.com
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - simplywall.st
Combining price and volume data for Milestone Pharmaceuticals Inc.Trade Risk Report & Capital Efficiency Focused Ideas - newser.com
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):